Evidence map›Paper›PMID 26664906›Full record

ArticleFrontiers in cardiovascular medicine2015

A Novel Method of Determining the Functional Effects of a Minor Genetic Modification of a Protein.

Janhavi Nagwekar, Divya Duggal, Krishna Midde, Ryan Rich, Jingsheng Liang, Katarzyna Kazmierczak, Wenrui Huang, Rafal Fudala, Ignacy Gryczynski, Zygmunt Gryczynski and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Janhavi NagwekarDepartment of Cell Biology, Center for Commercialization of Fluorescence Technologies, University of North Texas Health Science Center , Fort Worth, TX , USA.
Divya DuggalDepartment of Cell Biology, Center for Commercialization of Fluorescence Technologies, University of North Texas Health Science Center , Fort Worth, TX , USA.
Krishna MiddeDepartment of Cell Biology, Center for Commercialization of Fluorescence Technologies, University of North Texas Health Science Center , Fort Worth, TX , USA.
Ryan RichDepartment of Mathematics, Computer Science, and Physics, Texas Wesleyan University , Fort Worth, TX , USA.
Jingsheng LiangDepartment of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami , Miami, FL , USA.
Katarzyna KazmierczakDepartment of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami , Miami, FL , USA.
Wenrui HuangDepartment of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami , Miami, FL , USA.
Rafal FudalaDepartment of Cell Biology, Center for Commercialization of Fluorescence Technologies, University of North Texas Health Science Center , Fort Worth, TX , USA.
Ignacy GryczynskiDepartment of Cell Biology, Center for Commercialization of Fluorescence Technologies, University of North Texas Health Science Center , Fort Worth, TX , USA.
Zygmunt GryczynskiDepartment of Physics and Astronomy, Texas Christian University , Fort Worth, TX , USA.
Danuta Szczesna-CordaryDepartment of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami , Miami, FL , USA.
Julian BorejdoDepartment of Cell Biology, Center for Commercialization of Fluorescence Technologies, University of North Texas Health Science Center , Fort Worth, TX , USA.
University of Miami · USUniversity of North Texas · USUniversity of North Texas Health Science Center · USTexas Christian University · USTexas Wesleyan University · US

Funding

Novel cardioskeletal myopathy associated with MYL2R01HL123255 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SZCZESNA-CORDARY, DANUTA · 2015 to 2018
$2.0M
Novel Fluorophores for Molecular and Cellular ImagingR01EB012003 · NIBIB · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI GRYCZYNSKI, ZYGMUNT, YU, YIHUA BRUCE · 2011 to 2014
$1.8M
Single Cross-Bridge Kinetics in Transgenic Mouse Hearts Expressing FHC MutationsR01HL090786 · NHLBI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI BOREJDO, JULIAN, SZCZESNA-CORDARY, DANUTA · 2009 to 2012
$1.6M
Myosin ELC, a novel therapeutic target for FHCR01HL108343 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SZCZESNA-CORDARY, DANUTA · 2012 to 2015
$1.5M
Rotation of Single Cross-Bridge in Skeletal Muscle FiberR01AR048622 · NIAMS · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI BOREJDO, JULIAN · 2003 to 2007
$870k
NHLBI NIH HHS R01 HL090786NHLBI NIH HHS R01 HL108343NHLBI NIH HHS R01 HL123255NIAMS NIH HHS R01 AR048622NIBIB NIH HHS R01 EB012003
6 · The paper itself

Abstract

Contraction of muscles results from the ATP-coupled cyclic interactions of the myosin cross-bridges with actin filaments. Macroscopic parameters of contraction, such as maximum tension, speed of shortening, or ATPase activity, are unlikely to reveal differences between the wild-type and mutated (MUT) proteins when the level of transgenic protein expression is low. This is because macroscopic measurements are made on whole organs containing trillions of actin and myosin molecules. An average of the information collected from such a large assembly is bound to conceal any differences imposed by a small fraction of MUT molecules. To circumvent the averaging problem, the measurements were done on isolated ventricular myofibril (MF) in which thin filaments were sparsely labeled with a fluorescent dye. We isolated a single MF from a ventricle, oriented it vertically (to be able measure the orientation), and labeled 1 in 100,000 actin monomers with a fluorescent dye. We observed the fluorescence from a small confocal volume containing approximately three actin molecules. During the contraction of a ventricle actin constantly changes orientation (i.e., the transition moment of rigidly attached fluorophore fluctuates in time) because it is repetitively being "kicked" by myosin cross-bridges. An autocorrelation functions (ACFs) of these fluctuations are remarkably sensitive to the mutation of myosin. We examined the effects of Alanine to Threonine (A13T) mutation in the myosin regulatory light chain shown by population studies to cause hypertrophic cardiomyopathy. This is an appropriate example, because mutation is expressed at only 10% in the ventricles of transgenic mice. ACFs were either "Standard" (Std) (decaying monotonically in time) or "Non-standard" (NStd) (decaying irregularly). The sparse labeling of actin also allowed the measurement of the spatial distribution of actin molecules. Such distribution reflects the interaction of actin with myosin cross-bridges and is also remarkably sensitive to myosin mutation. The result showed that the A13T mutation caused 9% ACFs and 9% of spatial distributions of actin to be NStd, while the remaining 91% were Std, suggesting that the NStd performances were executed by the MUT myosin heads and that the Std performances were executed by non-MUT myosin heads. We conclude that the method explored in this study is a sensitive and valid test of the properties of low prevalence mutations in sarcomeric proteins.

Indexed as

actinautocorrelation functionfluorescence polarizationlow expressing mutationsmyosin light chainphalloidin-actin

Identifiers

PMID26664906
PMCPMC4671333
OpenAlexW2203579334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.